Literature DB >> 10798751

Immune reconstitution after allogeneic bone marrow transplantation depleted of T cells.

G M Davison1, N Novitzky, A Kline, V Thomas, L Abrahams, G Hale, H Waldmann.   

Abstract

BACKGROUND: Immune reconstitution following transplantation in individuals who had received T-cell-depleted marrow from HLA identical siblings was serially documented and correlated with the clinical recovery.
METHODS: Patients were preconditioned with radiation containing programs. GvHD prophylaxis was by T-cell depletion with CAMPATH 1G (ex vivo; median dose 20 mg). After transplantation lymphoid development was studied by flow cytometry and serum Ig concentrations were determined. Charts were reviewed to determine the effects of the immune reconstitution on the clinical performance.
RESULTS: The mean donor mononuclear cell number infused was 0.89x10(8)/kg. Within 6 months all the patients recovered their blood parameters and only one required therapy for GvHD. However, despite normal blood counts, 15 suffered life-threatening opportunistic infections, developing at a median of 24 weeks post grafting, but occurring even after 11 months. At 8 weeks from marrow infusion when leukocyte values had normalized in 15/20, compared to normal, immunophenotyping of blood cells from BMT revealed a significantly reduced mean lymphocyte count (1.06, SD 0.83x10(9)/l; P = 0.01), cells expressing CD3 (0.7x10(9)/l, SD 0.68; P = 0.05), CD4 (0.13x10(9)/l, SD 0.21; P = 0.0001) and CD19 (0.04x10(9)/l, SD 0.05; P = 0.001). Populations expressing CD8 and CD56 remained within normal range throughout the study. Normalization of cell numbers displaying CD2, CD3 and CD19 was delayed until 52, 52 and 24 weeks respectively, while CD4 counts persisted subnormal even at 72 weeks. Serum IgA levels were significantly decreased for the entire study period.
CONCLUSIONS: T-cell depletion with CAMPATH 1G while effectively preventing GvHD, also causes clinically significant and prolonged immunosuppression with apparently important clinical implications.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10798751     DOI: 10.1097/00007890-200004150-00022

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  8 in total

1.  Induction of tolerance to bone marrow allografts by donor-derived host nonreactive ex vivo-induced central memory CD8 T cells.

Authors:  Eran Ophir; Yaki Eidelstein; Ran Afik; Esther Bachar-Lustig; Yair Reisner
Journal:  Blood       Date:  2009-12-30       Impact factor: 22.113

2.  Immucillin H, a powerful transition-state analog inhibitor of purine nucleoside phosphorylase, selectively inhibits human T lymphocytes.

Authors:  G A Kicska; L Long; H Hörig; C Fairchild; P C Tyler; R H Furneaux; V L Schramm; H L Kaufman
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-03       Impact factor: 11.205

3.  Myc and AP-1 expression in T cells and T-cell activation in patients after hematopoietic stem cell transplantation.

Authors:  Shivtia Trop-Steinberg; Yehudith Azar; Rachel Bringer; Reuven Or
Journal:  Clin Exp Med       Date:  2014-08-07       Impact factor: 3.984

4.  Immunomagnetic isolation of CD4+CD25+FoxP3+ natural T regulatory lymphocytes for clinical applications.

Authors:  M Di Ianni; B Del Papa; D Cecchini; E Bonifacio; L Moretti; T Zei; R Iacucci Ostini; F Falzetti; L Fontana; G Tagliapietra; C Maldini; M F Martelli; A Tabilio
Journal:  Clin Exp Immunol       Date:  2009-03-09       Impact factor: 4.330

5.  Autoimmune thyroid disease following alemtuzumab therapy and hematopoietic cell transplantation in pediatric patients with sickle cell disease.

Authors:  Kristen M Williams; Danielle Dietzen; Abeer A Hassoun; Ilene Fennoy; Monica Bhatia
Journal:  Pediatr Blood Cancer       Date:  2014-06-17       Impact factor: 3.167

Review 6.  Transplantation of haploidentically mismatched stem cells for the treatment of malignant diseases.

Authors:  Franco Aversa; Massimo F Martelli
Journal:  Springer Semin Immunopathol       Date:  2004-09-11

Review 7.  Invasive fungal infection in haematopoietic stem cell transplant recipients: epidemiology from the transplant physician's viewpoint.

Authors:  E J Bow
Journal:  Mycopathologia       Date:  2009-04-03       Impact factor: 2.574

Review 8.  Alemtuzumab in stem cell transplantation.

Authors:  Geoff Hale
Journal:  Med Oncol       Date:  2002       Impact factor: 3.064

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.